AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

In the last few years, Chinese AI startup MiniMax has become one of the most exciting in the crowded global AI marketplace, ...

A sample collected by the Hayabusa 2 spacecraft from the spinning top-like asteroid contained the nucleobases adenine, ...

A new study reveals all five fundamental nucleobases – the molecular “letters” of life – have been detected in samples from ...

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

Investment bank Morgan Stanley has warned that a major breakthrough in artificial intelligence (AI) could arrive in the first half of 2026. This could be driven by a rapid expansion of computing power ...

The AI industry is constantly churning out news, like major acquisitions, indie developer successes, public outcry, and ...

All right. Good morning, again, for I see some familiar face in the last one, but thanks for sticking around. It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare ...

The rapid advancement of Artificial Intelligence has moved us from simple chatbots to autonomous agents. These agents do not just answer questions; they plan, use tools, and execute tasks with minimal ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Recursion Pharmaceuticals (RXRX) closed at $3.42 in the latest trading session, marking a -8.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.69%.